|Articles|March 15, 2021
- BioPharm International-03-15-2021
- Volume 2021 eBook
- Issue 1
A Real-World Approach to Evaluating Cleanroom Garments
Author(s)Anne Marie Dixon-Heathman
Traditional methods of testing cleanroom garments fail to test for dynamic conditions in the cleanroom. A holistic approach considers particulate shedding and heat load during processing, as well as the impact of laundering on garment life cycle.
Advertisement
Selecting the best cleanroom garments for a specific application is crucial to maintaining the integrity of aseptic processing areas. The author has developed an evaluation process, outlined in this article, that uses "real world" conditions to determine how well cleanroom garb will prevent particulate emission and maintain comfortable temperatures for operators.
Article details
BioPharm International
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 14–21
Citation
When referring to this article, please cite it as: A. Dixon-Heathman, “A Real-World Approach to Evaluating Cleanroom Garments," BioPharm International Regulatory Sourcebook eBook (March 2021).
Articles in this issue
over 4 years ago
It Takes a Bio/Pharma Villageover 4 years ago
Collaborative Efforts Address Key Data Integrity Challengesover 4 years ago
Can FDA Reinvent Inspections?over 4 years ago
Growing Pipeline of Antisense Oligonucleotides Prompts Guidanceover 4 years ago
Gene Therapies Target Neurodegenerative Diseasesover 4 years ago
FDA 2021 Guidance Agenda Sees Focus on Genericsover 4 years ago
Regulatory and Standard Setting Organizations DirectoryNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
